Catalyst Event

Gilead Sciences Inc (GILD) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/4/2026, 12:00:00 AM

OtherSentiment: Positive

Completion of the acquisition of Ouro Medicines in collaboration with Lakefront Biotherapeutics to expand the inflammation pipeline with T-cell engager therapies on June 4, 2026. Low impact estimated as this is a small-scale strategic acquisition; expected.

Korean Translation

2026년 6월 4일, 레이크프론트 바이오테라퓨틱스(Lakefront Biotherapeutics)와 협력하여 T세포 인게이저 치료제로 염증 파이프라인을 확장하기 위한 오우로 메디슨스(Ouro Medicines) 인수 완료가 예상됨. 소규모 전략적 인수에 따른 낮은 영향이 예상됨.

Related Recent Events

View Full Timeline